Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (630)	12/9/2002 4:38:28 PM
From: tuck	Read Replies (1) \| Respond to of 2240

One wonders why MEDX did not see fit to mention this transaction of almost a month ago: >>WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Dec. 9, 2002--Kyto Biopharma, Inc. ("Kyto Biopharma" or the "Company") is pleased to announce the following recent corporate developments. On November 11, 2002, Kyto Biopharma and Medarex Inc. ("Medarex") agreed to restructure certain aspects of their collaboration under a Research and Collaboration Agreement signed on January 15, 2001. In connection with the restructuring, Kyto Biopaharma has granted to Medarex a right of first negotiation to license human monoclonal antibody products developed under the collaboration and issued 800,000 of its common shares to Medarex. Medarex now has an approximate 19% ownership interest in Kyto Biopharma. On November 11, 2002, Credifinance Gestion S.A. ("CFG") agreed to terminate its anti-dilution protection over its ownership stake in the Company and has converted its $100,000 Convertible Debenture - Series A (the "Debenture") into 100,000 common shares of the Company. CFG has also released the security that it held against the assets of the Company. On November 22, 2002, Kyto Biopharma restructured the outstanding balance owed to New York University for services rendered by the issuance of 113,058 common shares in the Company. Kyto Biopharma is currently pursuing certain other unsecured creditors for the settlement of outstanding indebtedness aggregating $60,000 with common shares in the Company. The Company is currently responding to comments provided by the Securities and Exchange Commission with regards to its amended SB-2 filing. The Company intends to raise additional capital to advance its drug delivery platform through pre-clinical studies and undertake further immunization work with Medarex to generate fully human monoclonal antibodies against the targets provided by Kyto Biopharma to Medarex. The Company is actively seeking professionals to add to its management team and Board of Directors. Kyto Biopharma, Inc. Kyto Biopharma is a development stage biopharmaceutical company that develops receptor-mediated technologies to control the uptake of vitamin B12 by non-controlled proliferative cells. Vitamin B12 regulates one of two major cellular pathways for the production of folates, the cell's primary source of carbon and the progenitor for the synthesis of DNA. Kyto Biopharma has a portfolio of potential targeted biologic treatments based on (i) the delivery of cytotoxic drugs using the vitamin B12 as a vehicle, (ii) the therapeutic effect of vitamin B12 depletion by receptor-mediated "Growth Blockers" and (iii) the use of monoclonal antibodies issued of its vitamin B12 depletion technology. Depletion of vitamin B12 levels in abnormal rapid growth and deregulated cells, such as observed in cancer and some diseases of the immune system leads to inhibition of cellular proliferation and induction of apoptosis, or programmed cell death.<< snip This PR makes Kyto seem a bit desperate to me, as if they are low on cash so diluting and restructuring. The B12 approach seems off the wall, but I haven't looked at any abstracts. What do MEDX followers think of this investment? I don't suppose anybody in Kyto is related to anybody in MEDX? Cheers, Tuck

To: Icebrg who wrote (630)	12/13/2002 10:29:12 AM
From: nigel bates	Respond to of 2240

Just parking... HUDDINGE, Sweden, Dec. 13, 2002 (PRIMEZONE) -- Medivir (Stockholm: MVIRb.ST - news) and Paradigm Therapeutics Ltd (Cambridge, U.K.) have entered a broad-based, 3-year research collaboration to identify novel protease drug targets and discover protease inhibitor drugs. The collaboration will combine Medivir's expertise and technologies in protease inhibitor drug discovery, which includes proprietary screening methods and extensive protease inhibitor compound libraries, with Paradigm's bioinformatics, functional biology and drug target validation technologies. Together the partners will identify and validate up to six novel proteases as potential drug targets, and develop small-molecule protease inhibitor drugs. The alliance will focus on major human diseases consistent with Medivir's therapeutic interests. Drug products resulting from the partnership will be commercialised through either out- licensing or product sales. "This collaboration further broadens Medivir's protease inhibitor research pipeline, which already includes a number of well-established protease inhibitor programs," said Jonas Frick, Medivir's CEO. "Paradigm's expertise in novel target validation neatly complements Medivir's protease inhibitor drug discovery know-how and technologies." "Paradigm has established a powerful biological platform to define the potential clinical utility of large numbers of novel human drugable gene targets and is now ideally positioned to start the development of novel drugs to these targets," said Dr Richard Goodfellow, Commercial Director at Paradigm. "Proteases are increasingly recognized as important starting points for the development of new and effective drugs. We are therefore delighted to have forged an alliance with Medivir to exploit the potential for generating small-molecule drugs to Paradigm's novel protease targets." The Medivir Group Medivir is an innovative and specialized research company active in the pharmaceuticals sphere, located in Cambridge, U.K., and Huddinge, Sweden. Medivir's research focuses on the development of new pharmaceutical compounds as inhibitors of target enzymes with protease or polymerase activity. The group comprises Medivir AB, the subsidiaries Medivir UK Ltd and CCS AB, plus second-tier subsidiaries CCS (U.K.) Ltd and Nordic Care Sweden AB. Medivir has been listed on the Stockholm Stock Exchange since 1996. The research portfolio includes projects against HIV, jaundice, shingles, cold sores, osteoporosis, rheumatoid arthritis, asthma, multiple sclerosis and organ/graft rejection. Medivir has four projects in clinical development. Of these, two are moving towards Phase III trials after having completed Phase II trials. One is in Phase I and one is in Phase II. Medivir's pre-clinical research encompasses a number of projects, of which one is on its way towards and two are in the lead optimization phase and one is in the late pre-clinical development stage. A further ten activities are in the explorative stage. For more information about Medivir, visit the company's web site at www.medivir.com Paradigm Therapeutics Ltd The race to define the therapeutic utility of the thousands of uncharacterised human proteins is the new hallmark of modern drug discovery. Unlocking the precise physiological function of these proteins is a vital prerequisite of rational drug development. Paradigm, a privately held company that recently announced the successful completion of a second round of equity funding totaling 12 million pounds, has established a powerful genetics based platform that is generating detailed information and intellectual property on the physiological role, and hence the potential therapeutic utility and value of novel targets identified from within the human genome. Over 700 potential drugable targets have already been identified, of which 100 of the most exciting are well advanced within its biological validation program. Paradigm has already characterised targets that represent novel therapeutic points of intervention in key disease areas. Paradigm's commercial strategy is to develop both monoclonal and small molecule drugs to these targets in partnership with other drug development companies. The company has already formed a broad-based collaboration with Genmab (Copenhagen: GEN.CO - news) for the development of therapeutic antibodies. For more information visit the Paradigm web site: paradigm- therapeutics.co.uk.